NCT04704492View on ClinicalTrials.gov

A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 14, 2012

Primary Completion Date

December 16, 2013

Study Completion Date

December 16, 2013

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Biological: SM03

Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0,2

Trial Locations (1)

100032

Clinical Pharmacology Research Center & Translational Medicine Centre, Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

SinoMab BioScience Ltd

INDUSTRY

NCT04704492 - A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter